Compare American Express Co (AXP) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Express Co vs Moderna, Inc. — how do they compare? American Express Co trades at $344 (market cap $230.15B), while Moderna, Inc. trades at $63.7 (market cap $24.18B). The key difference: American Express Co is far larger — about 9.5× Moderna, Inc.'s market cap, and American Express Co pays a 1.11% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| AXP | MRNA | |
|---|---|---|
Market Cap | $230.15B | $24.18B |
Sector | Financials | Health |
52-Week High | $384.82 | $81.80 |
52-Week Low | $292.27 | $22.36 |
Dividend Yield | 1.11% | — |
Enterprise Value | — | $20.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AXP trades at $343.22, up 1.29% today, with a bullish technical signal and strong support at $339. The stock shows robust fundamentals with 2025 revenue of $72.23B and net income of $10.83B, though recent earnings have been mixed. Analyst consensus is a $369.42 price target with 40% buy ratings. Recent news highlights Amex Ventures' AI investments and premium cardmember benefits, reinforcing growth initiatives.
Outlook remains positive due to steady revenue growth and high ROE of 33.97%, but risks include competitive pressures and a P/E of 20.68 above sector averages. The stock offers upside to consensus targets if execution continues, though investors should monitor spending trends and economic sensitivity.
Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.
The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Express Co
American Express Company is a global payment and travel company. The Company's principal products and services are charge and credit payment card products and travel-related services offered to consumers and businesses around the world.
Read more on AXP →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
